Combination with inhibitors of the PI3K/AKT/mTOR pathway and the EGFR-TK inhibitor increases therapeutic effects by synergism against TNBC and NSCLC with resistance to EGFR-TK inhibitors [31,43]. Here, PIK3CA is linked to non-small cell lung carcinoma.